Literature DB >> 8701248

[Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)].

R Cadisch1, E Streit, K Hartmann.   

Abstract

We report the case of a 25-year-old female patient with severe aggravation of myasthenia gravis due to azithromycin which was prescribed for an influenza syndrome. One hour after the intake of 500 mg azithromycin the patient developed weakness of the legs and respiratory distress due to respiratory muscle failure. She was hospitalized in a comatose state and required intubation and mechanical ventilation for six days. Acute worsening of myasthenia gravis was observed in this patient in 1986 after parenteral administration of erythromycin. Erythromycin causing aggravation of myasthenia gravis by interfering with neuromuscular transmission is reported in the literature. The close temporal relationship between the intake of azithromycin and severe worsening of myasthenia gravis in our patient suggests that azithromycin, a new azalid-antibiotic of the macrolid group, can exacerbate myasthenia gravis. We conclude that azithromycin should be added to the list of drugs to be used with caution in patients with myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701248

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  6 in total

1.  Investigation on the mechanism of exacerbation of myasthenia gravis by aminoglycoside antibiotics in mouse model.

Authors:  Changqin Liu; Fang Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 2.  Macrolide antibiotics.

Authors:  R C Gordon
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

Review 3.  Pathophysiological basis in the management of myasthenia gravis: a mini review.

Authors:  Aiswarya Binu; Sarath S Kumar; Uma Devi Padma; Krishnadas Madhu
Journal:  Inflammopharmacology       Date:  2022-01-21       Impact factor: 4.473

4.  Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival.

Authors:  Michala Jakubíková; Michaela Týblová; Adam Tesař; Magda Horáková; Daniela Vlažná; Irena Ryšánková; Iveta Nováková; Kristýna Dolečková; Pavel Dušek; Jiří Piťha; Stanislav Voháňka; Josef Bednařík
Journal:  Eur J Neurol       Date:  2021-06-25       Impact factor: 6.288

Review 5.  TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.

Authors:  Sven Županić; Ines Lazibat; Maja Rubinić Majdak; Mia Jeličić
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.932

6.  COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).

Authors:  Srikanth Muppidi; Jeffrey T Guptill; Saiju Jacob; Yingkai Li; Maria E Farrugia; Amanda C Guidon; Jinny O Tavee; Henry Kaminski; James F Howard; Gary Cutter; Heinz Wiendl; Matthew B Maas; Isabel Illa; Renato Mantegazza; Hiroyuki Murai; Kimiaki Utsugisawa; Richard J Nowak
Journal:  Lancet Neurol       Date:  2020-12       Impact factor: 44.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.